TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed its 13th new provisional patent application and has advanced the build-out of its digital therapeutics strategy.
The company is evolving its programs beyond the psychedelic molecule, into an eco-system that may potentially drive improved patient treatments through the advancement of its digital therapeutics development.
Led by Cybins innovation team, including its newly formed patient steering committee, Cybin has commenced the next phase of the companys digital therapeutics platform which will better enable the evaluation of patient outcomes through a highly secure, patient-centered data analytics platform for better pre- and post- psychedelic treatments.
The digital therapeutics platform, which is proprietary to Cybin and the subject of the companys 13th patent application, adds another dimension to the companys development programs. The aim of utilizing and leveraging cutting-edge technologies to support drug development candidates will be a top priority as both the industry and the company evolves.
Combined with the companys recently announced collaboration with Kernel (quantitative neuroimaging technology), Greenbrook TMS (operator of 129 outpatient mental health service centers in the United States), and the progression of other proprietary tools such as the EMBARK psychotherapy model, Cybin is building an advanced eco-system that can drive innovation from the psychedelic molecule, delivery of the molecule, quantitative testing of the molecule in patients to late-stage trials and one day potential patient treatments.
About Cybin
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as may, should, could, intend, estimate, plan, anticipate, expect, believe or continue, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding enhanced liquidity, the value of additional capital markets exposure, access to institutional and retail investors, the Companys new strategic brand messaging campaign, and psychedelic drug development programs to potentially treat mental health disorders. There are numerous risks and uncertainties that could cause actual results and Cybins plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Cybin makes no medical, treatment or health benefit claims about Cybins proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.
The NEO Exchange has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.
Read the original:
Cybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy - Business Wire
- Despite currently being unprofitable, EDAP TMS (NASDAQ:EDAP) has delivered a 52% return to shareholders over 5 years - Simply Wall St - April 18th, 2024 [April 18th, 2024]
- BrainsWay Expands Deep TMS Access in Israel Following Significant Increase in Reimbursement Rates - GlobeNewswire - April 18th, 2024 [April 18th, 2024]
- Mastery Logistics Systems partners with Transflo to integrate Workflow AI with MasterMind TMS to deliver a ... - Business Wire - April 18th, 2024 [April 18th, 2024]
- New form of magnetic brain stimulation spells hope for patients with treatment-resistant depression - The Straits Times - April 18th, 2024 [April 18th, 2024]
- Port of Oakland's new TMS provides real-time insights for truckers - CCJ - February 5th, 2024 [February 5th, 2024]
- TMS Taps Michelson To Oversee Global Talent Development 01/02/2024 - MediaPost Communications - February 5th, 2024 [February 5th, 2024]
- 11.24% CAGR Growth in Transportation Management Systems (TMS) Market by Solution (on-premise and cloud-based ... - PR Newswire - February 5th, 2024 [February 5th, 2024]
- MileMaker announces partnership with Turvo to bring advanced TMS - TheTrucker.com - The Trucker - February 5th, 2024 [February 5th, 2024]
- Transportation Management Software & Solutions - Who are the Major Players in the Indian Market? - India Shipping News - February 5th, 2024 [February 5th, 2024]
- Neural effects of TMS trains on the human prefrontal cortex | Scientific Reports - Nature.com - December 25th, 2023 [December 25th, 2023]
- What to know about TMS and how it can treat mental health issues - News3LV - December 25th, 2023 [December 25th, 2023]
- Neuronetics lands FDA clearance for TMS therapy accessory - Medical Device Network - December 25th, 2023 [December 25th, 2023]
- Neurobiological mechanisms of ECT and TMS treatment in ... - BMC Psychiatry - October 31st, 2023 [October 31st, 2023]
- Mishimoto Partners with Redwood Logistics for Seamless TMS ... - Supply Chain Dive - October 31st, 2023 [October 31st, 2023]
- 3 benefits of integrating WMS and TMS software - TechTarget - October 31st, 2023 [October 31st, 2023]
- Trinium and BlueCargo join forces to increase resiliency and agility ... - American Journal of Transportation - October 31st, 2023 [October 31st, 2023]
- Psychiatrist Convicted of Billing Medicare and Private Insurance ... - Department of Justice - October 31st, 2023 [October 31st, 2023]
- FreightPOP TMS Application Earns Acumatica Certification - PR Web - October 31st, 2023 [October 31st, 2023]
- AML RightSource Offers Support for Transaction Monitoring System Selection and Integration - Global Banking And Finance Review - October 31st, 2023 [October 31st, 2023]
- TMS therapy: The cloud hanging over me was gone - WellSpan Health - May 18th, 2023 [May 18th, 2023]
- Depression Relief: Brain Signal Reversal by Magnetic Pulses - Neuroscience News - May 18th, 2023 [May 18th, 2023]
- HWS CENTER LAUNCHES TMS THERAPY, BRINGING CUTTING-EDGE MENTAL HEALTH TREATMENT TO NEW JERSEY - EIN News - May 18th, 2023 [May 18th, 2023]
- Incoming TMS students take tours of site - Yahoo News - May 18th, 2023 [May 18th, 2023]
- Passion Drives TMS Titanium's Todd Harrison - Drag Illustrated - May 18th, 2023 [May 18th, 2023]
- EDAP TMS S A : Positive results from two studies reconfirm safety ... - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Shiba Inu (SHIB) Whale Purchasing Into The TMS Network (TMSN ... - Analytics Insight - May 18th, 2023 [May 18th, 2023]
- TMS Coils Market 2023 Business Growth and Opportunities with Top ... - Cottonwood Holladay Journal - May 18th, 2023 [May 18th, 2023]
- The Top Cryptos To Buy In 2023 - Arbitrum, Polygon and TMS Network - Analytics Insight - May 18th, 2023 [May 18th, 2023]
- Accelerated delivery of transcranial magnetic stimulation is safe and effective - Newswise - May 18th, 2023 [May 18th, 2023]
- Polygon (MATIC) and Solana (SOL) Drop by 10%, While TMS ... - Crypto Reporter - May 18th, 2023 [May 18th, 2023]
- VeChain (VET) & Curve DAO Token (CRV) Investors Diversify Their ... - Analytics Insight - May 18th, 2023 [May 18th, 2023]
- As Cardano (ADA) Stumbles And Dogecoin (DOGE) Falters, TMS ... - UseTheBitcoin - May 18th, 2023 [May 18th, 2023]
- Nexstim's Quality System and NBS 6 Receive MDR - GlobeNewswire - May 18th, 2023 [May 18th, 2023]
- Uniswap (UNI) and Shiba Inu (SHIB) Underwater as Crypto Looks ... - The Merkle Hash - May 18th, 2023 [May 18th, 2023]
- NeuroStim TMS Celebrates Landmark Achievement, Delivering Over 100,000 TMS Treatments Upon Reaching Five Year Anniversary - Yahoo Finance - May 6th, 2023 [May 6th, 2023]
- Modeling the antidepressant treatment response to transcranial ... - Nature.com - May 6th, 2023 [May 6th, 2023]
- USD Coin (USDC) & Optimism (OP)'s Investors Are Aping Into TMS ... - Analytics Insight - May 6th, 2023 [May 6th, 2023]
- TMS Network (TMSN) Presale Gains 2400%: Optimism (OP) and ... - Analytics Insight - May 6th, 2023 [May 6th, 2023]
- The Best Anime By TMS Entertainment - GameRant - May 6th, 2023 [May 6th, 2023]
- TMS Network (TMSN) Predicted To Pass Shiba Inu (SHIB) And Stacks (STX) In Popularity Within A Year | - Bitcoinist - May 6th, 2023 [May 6th, 2023]
- Towering Over Solana (SOL) and Dogecoin (DOGE), TMS Network (TMSN) Takes the Crown | Bitcoinist.com - Bitcoinist - May 6th, 2023 [May 6th, 2023]
- Market Corrections Push Cardano (ADA) and Polygon (MATIC ... - Analytics Insight - May 6th, 2023 [May 6th, 2023]
- Chainlink vs TMS Network vs TRON : One of them With Deliver ... - The Coin Republic - May 6th, 2023 [May 6th, 2023]
- PCS Software Named a Preferred Partner as Kuebix TMS Sunsets - Benzinga - May 6th, 2023 [May 6th, 2023]
- Could Musk Suit Have Negative Impact on Dogecoin (DOGE) and ... - Crypto Reporter - May 6th, 2023 [May 6th, 2023]
- The Future of Logistics: How Technology is Revolutionizing the ... - Robotics and Automation News - May 6th, 2023 [May 6th, 2023]
- Baru Gold Designated "National Vital Object" and Updates ... - Junior Mining Network - May 6th, 2023 [May 6th, 2023]
- Early Bird offer for TMS Awards - The Maritime Standard - May 6th, 2023 [May 6th, 2023]
- St Helen's Hospital patient says many are 'devastated' by its imminent closure - ABC News - May 6th, 2023 [May 6th, 2023]
- Transcranial Magnetic Stimulation (TMS) | Sibley Memorial Hospital in ... - March 31st, 2023 [March 31st, 2023]
- Psychiatry | Sibley Memorial Hospital in Washington, D.C. - March 31st, 2023 [March 31st, 2023]
- Want To Win Big? Experts Suggest To Choose TMS Network (TMSN) Over Arbitrum (ARB) And Polygon (MATIC) | - Bitcoinist - March 31st, 2023 [March 31st, 2023]
- TMS Network (TMSN) AI Infrastructure Will Give You 100x Returns, Way Better Than SingularityNET (AGIX) And - Bitcoinist - March 31st, 2023 [March 31st, 2023]
- TMS: What It Felt Like for Me I Psych Central - February 20th, 2023 [February 20th, 2023]
- Are we in a recession? Crypto giant Bitcoin and Ethereum stall out while TMS Network makes its mark - FXStreet - February 20th, 2023 [February 20th, 2023]
- Are GameFi coins like SHIB and Decentraland (MANA) as good of a long term investment as TMS Network? - FXStreet - February 20th, 2023 [February 20th, 2023]
- Launch of New Tron (TRX)-powered AI on the Way, Doritos Launches Project on Polygon (MATIC) While TMS Network (TMSN) Brings New Hopes for Brighter... - February 20th, 2023 [February 20th, 2023]
- What is a Transportation Management System? | Oracle - January 31st, 2023 [January 31st, 2023]
- TMS (Transcranial Magnetic Stimulation): What It Is - January 19th, 2023 [January 19th, 2023]
- HC Wainwright Adjusts Price Target on EDAP TMS S.A to $12 From $11, Maintains Buy Rating - Marketscreener.com - November 21st, 2022 [November 21st, 2022]
- Breakthrough in brain stimulation offers cautious hope for depression - Harvard Health - October 21st, 2022 [October 21st, 2022]
- Life-changing treatment program in Ohio expanding for veterans and first responders - WTRF - October 19th, 2022 [October 19th, 2022]
- Over 60% Of Pokemon Fans Are Most Excited For This Feature In Scarlet & Violet - SVG - October 19th, 2022 [October 19th, 2022]
- Radaro and NorthStar Digital Solutions partner to solve industry-wide process gaps in LTL & TL transportation - PR Newswire - October 19th, 2022 [October 19th, 2022]
- Avalanche Technology and TMS-Elektronik Announce Representation Agreement for the Republic of Turkey - PR Web - October 17th, 2022 [October 17th, 2022]
- Global Talent Management Software (TMS) Market Report 2022: A $25+ Billion Market by 2027 - Industry Trends, Share, Size, Growth, Opportunities and... - October 17th, 2022 [October 17th, 2022]
- A Foreword to Adam Smith's The Theory of Moral Sentiments - Independent Institute - October 17th, 2022 [October 17th, 2022]
- Deutsche Telekom to buy 100% electric company cars from 2023 - www.electrive.com - October 17th, 2022 [October 17th, 2022]
- What Happens in the Brain During Transcranial Magnetic Stimulation? - Technology Networks - October 13th, 2022 [October 13th, 2022]
- TMS and SIS to vie for soccer championship - Saipan Tribune - October 13th, 2022 [October 13th, 2022]
- Soterix Medical Announces award of Fast Track NIH grant to develop a Parcel-Guided software to improve efficacy of rTMS treatment for Depression - PR... - October 13th, 2022 [October 13th, 2022]
- Interview: Kindra Neely Talks Healing Through Art and Personal Hope in 'Numb to This' - The Mary Sue - October 13th, 2022 [October 13th, 2022]
- Local veteran finds success with TMS therapy | Local News | thenewsenterprise.com - Elizabethtown News Enterprise - September 29th, 2022 [September 29th, 2022]
- Racin' Today Everything's Big In Texas Including Criticism Of TMS - RacinToday.com - September 29th, 2022 [September 29th, 2022]
- Start over from scratch: Race weekend at TMS stirs up track reconfiguration rumors - The Dallas Morning News - September 29th, 2022 [September 29th, 2022]
- $28 Billion Transportation Management System Markets - Global Forecast to 2027: Increasing Demand for TMS to Tackle High Demand from e-Commerce -... - September 29th, 2022 [September 29th, 2022]
- EDAP TMS Hosting Urology Expert Panel and Live Focal One Technology Demonstration - GlobeNewswire - September 29th, 2022 [September 29th, 2022]
- Reddick prevails in wild race that sees record number of yellow flags at TMS - Denton Record Chronicle - September 29th, 2022 [September 29th, 2022]
- e2log and Wipro Discuss How Technology Accelerates Logistics Engines That Drive Global Supply Chains at Gartner Supply Chain Symposium/Xpo 2022 EMEA -... - September 29th, 2022 [September 29th, 2022]
- Transcranial Magnetic Stimulators Market Size And Forecast To 2022 |eNeura BrainsWay Ltd., MagVenture, Nexstim Plc, TMS Neuro Solutions, Magstim The... - September 29th, 2022 [September 29th, 2022]